Excipients in Pharmaceuticals

Published - Sep 2009| Analyst - Bob Frost| Code - PHM010F
Market Research Report Single User License: $2750 Member Price: FREE

Report Highlights

  • Overall sales in the global excipients market were worth $4.1 billion in 2008, and increased to an estimated $4.3 billion in 2009. By 2014, it is projected to increase to $5.9 billion, for a 5-year compound annual growth rate (CAGR) of 6.3%.
  • The largest segment of the market, organic chemicals, was valued at $3.8 billion in 2008; this is expected to increase to $4 billion in 2009, and is projected to reach $5.5 billion in 2014, for a 5-year CAGR of 6.4%.
  • Sales in the USP (U.S. Pharmacopeia-grade) Water segment amounted to $79 million in 2008, increased to an estimated $84 million in 2009, and is projected to increase to $104 million in 2014, for a 5-year CAGR of 4.4%.



Powerful forces affect the global excipients industry in 2009, including a crisis in the global supply chain, the demands of Quality by Design (QbD), worries about drug safety, new legislation in the offing, a need for new excipients, exciting ideas for unlocking the industry’s creativity, and new levels of cooperation between major players (e.g., Dow and Colorcon). These forces are reshaping the business rapidly. In addition, as if these factors were not enough, companies are also contending with a nasty recession. Up-to-date information is essential for competitors. 
The primary goals of this technical/market report are to provide a detailed analysis of the excipients market today and a forecast of what the market will look like in 5 years. The specific objectives (1) identify excipients being used; (2) quantify global market volume; (3) track important developments; (4) analyze the structure of the industry and its driving forces; (5) examine the most active companies and describe how they respond to market demands; and (6) provide data with which the reader can further evaluate the industry.
As a market and technology summary, this report consolidates a wide range of industrial and technical information that should aid excipient suppliers, chemical companies, drug manufacturers, healthcare regulators, and congressional staffers keep current with today’s marketplace. The report should be of value to companies interested in entering or expanding their involvement in the field. The report should provide senior marketing personnel and executive planners with insight about what materials can best satisfy customer demands. Market projections may be of interest to venture capitalists interested in exploring commercialization opportunities, as well as companies and personnel involved in designing and constructing chemical and excipient manufacturing plants and/or those who service such plants. The report offers useful background to consultants in the field. The report can serve as an introductory resource for newcomers to the business, including new employees. In addition, the report can offer background to governmental officials examining reform. 
Excipients in Pharmaceuticals offers coverage of the most important issues surrounding excipients: technological, regulatory, economic, political, and so on.  
Excluded from the study are ingredients for cosmetics, personal care, food, quasi-medical, unorthodox, alternative, home remedies, underground and/or illegal drugs, and veterinary drugs.
This report organizes information from diverse sources into sections entitled Summary, Overview, Technology, Industry Structure, and Company Profiles. The Summary encapsulates several key conclusions and includes a table of market findings. The Overview provides deep background on the burning issues of the day, including the global supply chain crisis, QbD, and legislative prospects. The Technology section examines excipients by chemical compounds, functional uses, and delivery systems, and as finished products. The Industry Structure section discusses the market environment, strategies, influences, market shares, international aspects, and other related factors. The Company Profiles segment provides summaries of more than 120 companies that supply excipients or are relevant to the industry.
The methodology used to create Excipients in Pharmaceuticals included extensive telephone interviews with key executives of leading U.S. and European companies and consultancies. This commentary was combined with information gleaned from websites, annual reports, the trade press, textbooks, patents, press releases, and government documents. 
The information has been used to project and forecast market size, and calculate compound annual growth rates (CAGRs) of the overall market and many market segments. All market sizes refer to worldwide values and volumes, which are rounded to the nearest million in dollars and lbs. Market size is estimated at the manufacturer level; that is, the level of consumption in actual drug formulations. Where precise information was not available, a consensus was made using a formulation of reasonable assumptions and estimates based on historical data. In this report, the market size for 2008 serves as a base for making estimates for 2009 and projections to 2014.
BCC Research analyst Bob Frost has studied and written about many health-related topics. He spent a number of years covering health, including technological innovations in healthcare, for West, the award-winning Sunday magazine of The San Jose Mercury News, newspaper of record for Silicon Valley. He has also studied and written about quality management, re-engineering, change management, and other business and technical topics for several major publications, including internal publications of the telecommunications company, Pacific Bell. In 1996, he wrote a book describing each of Pacific Bell’s 250 re-engineering projects. 
BCC offers online services at bccresearch.com. Readers can:
  • Examine BCC’s complete catalog of Market Research Reports, and place orders
  • Subscribe to BCC’s many industry newsletters
  • Read announcements of recently published reports and newly launched newsletters
  • Register for BCC’s well-known conferences
  • Request additional information on BCC products
  • Take advantage of special offers.
The information in this report is intended to be as reliable as possible at the time of publication. This information does not constitute managerial, legal, or accounting advice, nor should it serve as a corporate policy guide or laboratory manual, nor as an endorsement of any product. The information here is developed carefully from informed sources, but much of it is speculative in nature. The author and publisher assume no responsibility for any loss or damage that might result from use or reliance on information in this report.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
Published - Jun-2007| Analyst - Norma Corbitt| Code - PHM010E

Report Highlights

  • The chemical compounds used to make excipients are valued at $4.3 billion market value for 2011, up from $3.5 billion in 2006. The dominance of USP water, particularly water for injection, skews the market volume and sets the pace for the anticipated 5.1% average annual market volume growth rate over the next five years.
  • Formulators will continue to use excipients to give their final drug products the necessary or desired functional use or properties. Vehicles, with an estimated 2011 market volume of 9.6 billion pounds, lead due to the large amount of USP water consumed.
  • Fillers follow with an estimated 849 million pounds of excipient chemical compounds being used in that functional category in five years. In terms of market value, the situation is reversed. Fillers come out on top, with an estimated 2011 market value of $1.2 billion, and vehicles drop to third place with $781 million, just below emollients at $816 million.

Published - Dec-2002| Analyst - Charles Forman| Code - PHM010D

Report Highlights

  • In 2001, the global market for pharmaceutical (drug) inert ingredients was an estimated 7.25 billion pounds, of which water, accounted for about 77% of the total.
  • Overall growth of all drug inert ingredients is the order of 5% per year.
  • Injectables, essentially all Rx, constitute the single largest dosage form of excipients used in 2001 with almost 1.9 billion Kgs.
  • Nonaqueous biological use will grow to 563 million Kgs by 2007, an average annual growth rate (AAGR) of 4.5%.


Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report